Yutaro Obara

Yamagata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma.

Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma.

Journal: International journal of oncology

Published: October 15, 2025

Molecular Function of Midnolin and Its Relevance to Parkinson's Disease.

Molecular Function of Midnolin and Its Relevance to Parkinson's Disease.

Journal: Molecular and cellular biology

Published: July 22, 2025

Midnolin gene expression is enhanced by Gq-coupled muscarinic acetylcholine receptor stimulation in SH-SY5Y human neuroblastoma cells.

Midnolin gene expression is enhanced by Gq-coupled muscarinic acetylcholine receptor stimulation in SH-SY5Y human neuroblastoma cells.

Journal: Journal of pharmacological sciences

Published: December 12, 2024

Midnolin, a Genetic Risk Factor for Parkinson's Disease, Promotes Neurite Outgrowth Accompanied by Early Growth Response 1 Activation in PC12 Cells.

Midnolin, a Genetic Risk Factor for Parkinson's Disease, Promotes Neurite Outgrowth Accompanied by Early Growth Response 1 Activation in PC12 Cells.

Journal: Molecular and cellular biology

Published: September 12, 2024

Structural Variants of Midnolin, a Genetic Risk Factor for Parkinson's Disease, in a Yamagata Cohort.

Structural Variants of Midnolin, a Genetic Risk Factor for Parkinson's Disease, in a Yamagata Cohort.

Journal: Biological & pharmaceutical bulletin

Published: March 01, 2023

Effect of Extracellular Signal-Regulated Protein Kinase 5 Inhibition in Clear Cell Renal Cell Carcinoma.

Effect of Extracellular Signal-Regulated Protein Kinase 5 Inhibition in Clear Cell Renal Cell Carcinoma.

Journal: International journal of molecular sciences

Published: June 22, 2022

Insulin Enhances Gene Expression of Midnolin, a Novel Genetic Risk Factor for Parkinson's Disease, via Extracellular Signal-Regulated Kinase, Phosphoinositide 3-Kinase and Multiple Transcription Factors in SH-SY5Y Cells.

Insulin Enhances Gene Expression of Midnolin, a Novel Genetic Risk Factor for Parkinson's Disease, via Extracellular Signal-Regulated Kinase, Phosphoinositide 3-Kinase and Multiple Transcription Factors in SH-SY5Y Cells.

Journal: The Journal of pharmacology and experimental therapeutics

Published: December 27, 2021

ERK5 inhibitor BIX02189 attenuates methamphetamine-induced hyperactivity by modulating microglial activation in the striatum.

ERK5 inhibitor BIX02189 attenuates methamphetamine-induced hyperactivity by modulating microglial activation in the striatum.

Journal: Journal of pharmacological sciences

Published: August 04, 2021

Azelnidipine treatment reduces the expression of Cav1.2 protein.

Azelnidipine treatment reduces the expression of Cav1.2 protein.

Journal: Life sciences

Published: October 19, 2020

Reply to: MIDN locus structural variants and Parkinson's disease risk.

Reply to: MIDN locus structural variants and Parkinson's disease risk.

Journal: Annals of clinical and translational neurology

Published: February 02, 2020

Midnolin is a confirmed genetic risk factor for Parkinson's disease.

Midnolin is a confirmed genetic risk factor for Parkinson's disease.

Journal: Annals of clinical and translational neurology

Published: August 26, 2019

KCNQ1 is internalized by activation of α1 adrenergic receptors.

KCNQ1 is internalized by activation of α1 adrenergic receptors.

Journal: Biochemical pharmacology

Published: May 30, 2019

Showing 1-12 of 30

Last Updated: 09/26/2026